President & Chief Executive Officer
ProMetic Life Sciences Inc.
Mr. Pierre Laurin is a senior executive with 28 years of experience in the pharmaceutical and biotechnology industry. Involved in the development of ProMetic's platform technology since 1989, Mr. Laurin founded ProMetic Life Sciences Inc. in 1994. As Chairman until March, 2011 and President and CEO of the Corporation since its inception, he took the Corporation public on the Toronto Stock Exchange and has since raised over $430 million through equity and debt financing and multinational funding. Mr. Laurin’s corporate development achievements include the successful close of some 45 licensing agreements and joint venture agreements with multinationals including two strategic agreements with the American Red Cross. Mr. Laurin’s prior experience also includes positions with various pharmaceutical companies, including Nordic Laboratories (now Sanofi) where he played a pivotal role in the commercial success of Cardizem in Canada.
Mr. Laurin holds a B.Sc. in Pharmacy and a Master degree in Pharmaceutical Sciences from the University of Montreal.
Chief Financial Officer
ProMetic Life Sciences Inc.
Prior to his nomination as Chief Financial Officer of the ProMetic Group, Mr. Bruce Pritchard was formerly Chief Financial Officer of the U.K. affiliate ProMetic BioSciences Ltd (PBL). Mr.Pritchard is a Chartered Accountant with many years of experience in corporate accountancy including senior finance positions with biotech and pharmaceutical companies. Mr Pritchard has a proven track record of success in strategic acquisitions and raising finance from public and private sources. Mr.Pritchard is currently Chairman of the Institute of Chartered Accountants of Scotland’s England & Wales Area Committee and is a Trustee and Non-Executive Director of The Scottish Global Health Foundation.
Mr.Pritchard is a graduate of Heriot-Watt University where he gained a BA in Accountancy and Computer Science in 1993. He qualified as a Member of the Institute of Chartered Accountants of Scotland in 1996.
Senior Legal Counsel &
ProMetic Life Sciences Inc.
Mr. Patrick Sartore joined ProMetic in 2006 as Senior Legal Counsel – Intellectual Property and has since been nominated as Corporate Secretary of the Company. Mr. Sartore was previously employed by Univalor Inc. as Legal Counsel and Leger Robic Richard, L.L.P., a firm specializing in Intellectual Property, Corporate and Commercial Law, as an Associate Attorney. Mr. Sartore has extensive experience in the areas of Intellectual Property (prosecution and management of Patent and Trademark portfolios), Technology Transfer (Licencing Agreements, Material Transfer Agreements and Research and Development Contracts), private and public financing (Venture Capital, Institutional, Debt, Equity) as well as general corporate and commercial law. Mr. Sartore graduated from the University of Montreal with a Bachelor of Law (LLB) in 1999 and was called to the Bar of Quebec in 2001. Mr. Sartore also holds a Bachelor of Science, with Distinction, from Concordia University and is currently completing his Masters degree in taxation at the HEC Montreal. Mr. Sartore is a member of the Intellectual Property Institute of Canada and the Young Bar Association of Montreal.
Senior Vice-President of Product and Asia-Pacific Development
ProMetic BioTherapeutics Inc.
Dr. Dwun-Hou (Tom) Chen has been working at ProMetic BioTherapeutics Inc. (“PBT”) since its inception in 2006. First as Vice President of the Process Development Department to lead the process development work related to the Plasma Protein Purification System (“PPPS®”) project, then, as Vice President of Product and Asia Pacific Development, expanding his responsibility to include commercialization of the PPPS® technology in Asia Pacific region.
Prior to joining PBT, Dr. Chen was the Director of the Process Development at the Plasma Derivatives Department at American Red Cross where he was responsible for developing processes for a platform technology to be used in plasma fractionation.
Other past work experiences include Director of the Pharmaceutical Sciences Department at EntreMed Inc., Principle Scientist of the Discovery Research at Genetics Institute, Group Leader of the Protein Chemistry group at MetaMorphix, Inc. and Manager of the Protein Core Facility at Regeneron Pharmaceuticals, Inc.
Dr. Chen obtained BS degree in Chemistry from Tamkang University, Taiwan in 1979, and Ph.D. degree in Biochemistry from Auburn University, AL, USA in 1989; and had the post-doctoral training in both Wistar Institute and University of Pennsylvania.
Chief Executive Officer
ProMetic BioSciences Ltd
Dr. Steven J. Burton has over 22 years of experience in the development of separation processes and materials for the purification of biopharmaceuticals. He was instrumental in the development of Mimetic Ligands™, many of which are currently used as part of industrial bioseparation processes. Dr. Burton is responsible for the creation of a research and development facility at the University of Cambridge; a leading centre for the development of synthetic affinity ligand products and associated purification processes.
After first joining as Research and Development Manager in 1988, Dr. Burton was appointed to the Board of PBL in 1993. In January 1999, Dr. Burton was appointed Vice-President, Research and Development of ProMetic BioSciences Ltd and in 2003, he was promoted to Executive Vice-President with responsibility for ProMetic’s Enabling Technology Business Unit.
From 1986 to 1988, Dr. Burton was a research scientist at Delta Biotechnology, Ltd. where he was responsible for the development of downstream processes for large-scale purification of recombinant protein therapeutics.